Literature DB >> 17255094

Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins.

Ian V J Murray1, Liu Liu, Hiroaki Komatsu, Kunihiro Uryu, Gang Xiao, John A Lawson, Paul H Axelsen.   

Abstract

Evidence of oxidative stress and the accumulation of fibrillar amyloid beta proteins (Abeta) in senile plaques throughout the cerebral cortex are consistent features in the pathology of Alzheimer disease. To define a mechanistic link between these two processes, various aspects of the relationship between oxidative lipid membrane damage and amyloidogenesis were characterized by chemical and physical techniques. Earlier studies of this relationship demonstrated that oxidatively damaged synthetic lipid membranes promoted amyloidogenesis. The studies reported herein specify that 4-hydroxy-2-nonenal (HNE) is produced in both synthetic lipids and human brain lipid extracts by oxidative lipid damage and that it can account for accelerated amyloidogenesis. Abeta promotes the copper-mediated generation of HNE from polyunsaturated lipids, and in turn, HNE covalently modifies the histidine side chains of Abeta. HNE-modified Abeta have an increased affinity for lipid membranes and an increased tendency to aggregate into amyloid fibrils. Thus, the prooxidant activity of Abeta leads to its own covalent modification and to accelerated amyloidogenesis. These results illustrate how lipid membranes may be involved in templating the pathological misfolding of Abeta, and they suggest a possible chemical mechanism linking oxidative stress with amyloid formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255094      PMCID: PMC2253689          DOI: 10.1074/jbc.M608589200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein.

Authors:  Stefan Pype; Dieder Moechars; Lieve Dillen; Marc Mercken
Journal:  J Neurochem       Date:  2003-02       Impact factor: 5.372

Review 2.  4-Hydroxy-2-nonenal: a product and mediator of oxidative stress.

Authors:  Koji Uchida
Journal:  Prog Lipid Res       Date:  2003-07       Impact factor: 16.195

Review 3.  Transgenic C. elegans as a model in Alzheimer's research.

Authors:  Yanjue Wu; Yuan Luo
Journal:  Curr Alzheimer Res       Date:  2005-01       Impact factor: 3.498

4.  Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.

Authors:  Luigi Puglielli; Avi L Friedlich; Kenneth D R Setchell; Seiichi Nagano; Carlos Opazo; Robert A Cherny; Kevin J Barnham; John D Wade; Simon Melov; Dora M Kovacs; Ashley I Bush
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

5.  Study of protein modification by 4-hydroxy-2-nonenal and other short chain aldehydes analyzed by electrospray ionization tandem mass spectrometry.

Authors:  François Fenaille; Philippe A Guy; Jean-Claude Tabet
Journal:  J Am Soc Mass Spectrom       Date:  2003-03       Impact factor: 3.109

6.  Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia.

Authors:  Y Yao; V Zhukareva; S Sung; C M Clark; J Rokach; V M-Y Lee; J Q Trojanowski; D Praticò
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

Review 7.  Basic aspects of the biochemical reactivity of 4-hydroxynonenal.

Authors:  R J Schaur
Journal:  Mol Aspects Med       Date:  2003 Aug-Oct

8.  Mass spectroscopic characterization of protein modification by 4-hydroxy-2-(E)-nonenal and 4-oxo-2-(E)-nonenal.

Authors:  Zhongfa Liu; Paul E Minkler; Lawrence M Sayre
Journal:  Chem Res Toxicol       Date:  2003-07       Impact factor: 3.739

9.  Induction of redox instability of bovine myoglobin by adduction with 4-hydroxy-2-nonenal.

Authors:  A L Alderton; C Faustman; D C Liebler; D W Hill
Journal:  Biochemistry       Date:  2003-04-22       Impact factor: 3.162

10.  Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

Authors:  Carlos Opazo; Xudong Huang; Robert A Cherny; Robert D Moir; Alex E Roher; Anthony R White; Roberto Cappai; Colin L Masters; Rudolph E Tanzi; Nibaldo C Inestrosa; Ashley I Bush
Journal:  J Biol Chem       Date:  2002-08-20       Impact factor: 5.157

View more
  38 in total

1.  Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer's disease.

Authors:  A-Ryeong Gwon; Jong-Sung Park; Thiruma V Arumugam; Yong-Kook Kwon; Sic L Chan; Seol-Hee Kim; Sang-Ha Baik; Sunghee Yang; Young-Kwang Yun; Yuri Choi; Saerom Kim; Sung-Chun Tang; Dong-Hoon Hyun; Aiwu Cheng; Charles E Dann; Michel Bernier; Jaewon Lee; William R Markesbery; Mark P Mattson; Dong-Gyu Jo
Journal:  Aging Cell       Date:  2012-04-09       Impact factor: 9.304

2.  The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption.

Authors:  Justin Legleiter; John D Fryer; David M Holtzman; Andtomasz Kowalewski
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

Review 3.  Amyloid-β production: major link between oxidative stress and BACE1.

Authors:  Elena Tamagno; Michela Guglielmotto; Debora Monteleone; Massimo Tabaton
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

4.  Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.

Authors:  Marzia Perluigi; Rukhsana Sultana; Giovanna Cenini; Fabio Di Domenico; Maurizio Memo; William M Pierce; Raffaella Coccia; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2009-06-01       Impact factor: 3.494

5.  Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity.

Authors:  Kenji Usui; John D Hulleman; Johan F Paulsson; Sarah J Siegel; Evan T Powers; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

6.  Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro.

Authors:  Mukesh Maheshwari; Jessica K Roberts; Brent Desutter; Karen T Duong; Joseph Tingling; Janelle N Fawver; Hayley E Schall; Michael Kahle; Ian V J Murray
Journal:  Biochemistry       Date:  2010-11-17       Impact factor: 3.162

Review 7.  Cellular membrane fluidity in amyloid precursor protein processing.

Authors:  Xiaoguang Yang; Grace Y Sun; Gunter P Eckert; James C-M Lee
Journal:  Mol Neurobiol       Date:  2014-02-20       Impact factor: 5.590

Review 8.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

9.  Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.

Authors:  Michela Guglielmotto; Luca Giliberto; Elena Tamagno; Massimo Tabaton
Journal:  Front Aging Neurosci       Date:  2010-02-09       Impact factor: 5.750

10.  Amyloid-β(1-42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity.

Authors:  Sha Jin; Niraja Kedia; Eva Illes-Toth; Ivan Haralampiev; Simon Prisner; Andreas Herrmann; Erich E Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-07-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.